NHLBI Program Project Applications (P01 Clinical Trials Optional)
ID: 351057Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351057

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-065.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for Program Project Applications (P01) through the National Heart, Lung, and Blood Institute (NHLBI) to support innovative research on heart, lung, blood, and sleep disorders. Applicants are required to propose a minimum of three interrelated research projects centered around a common biomedical theme, with the option to include a project led by an Early Stage Investigator (ESI). This initiative aims to foster interdisciplinary collaboration and accelerate scientific knowledge acquisition, particularly encouraging participation from underrepresented groups in research. The maximum funding available is $1,515,000 in direct costs annually, with ESI-led projects eligible for up to $1,765,000. The application deadline is January 25, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-065.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-065-Full-Announcement.html
    Please provide the text you would like summarized.
    PAR-24-065.html
    The National Heart, Lung, and Blood Institute (NHLBI) has issued a Notice of Funding Opportunity (NOFO) for Program Project (P01) applications, inviting investigators to submit proposals that encompass at least three interrelated research projects focused on the biology and diseases of the cardiovascular, pulmonary, and hematological systems. Applications must align with NIH guidelines for budget and include a minimum of $1,515,000 in direct costs per year, with a maximum project period of five years, while ensuring compliance with Data Management and Sharing Plans starting January 25, 2023. Key dates for application submission include January 25, 2024, and repeated cycles through September 25, 2026, with budgetary considerations based on the number of projects and inclusion of Early Stage Investigators.
    Similar Opportunities
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity (FON: PAR-24-173) aimed at supporting Phase I clinical trials for therapeutics and diagnostics related to heart, lung, blood, and sleep (HLBS) disorders in both adults and children. This initiative utilizes a bi-phasic R61/R33 award mechanism, where the R61 phase focuses on preparatory activities such as finalizing trial protocols and gathering preclinical data, while the R33 phase is dedicated to executing the clinical trial. The funding limits include up to $250,000 annually for the R61 phase and $1,515,000 for the R33 phase, with total support available for a maximum of five years. Interested applicants must adhere to NIH guidelines and submit their proposals by January 7, 2027, to be considered for this opportunity. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Trial Pilot Studies (R34 Clinical Trial Optional) through the National Heart, Lung, and Blood Institute (NHLBI). This initiative aims to support research that provides essential information for the design of future Phase II-IV clinical trials focused on heart, lung, blood, and sleep disorders, requiring applicants to demonstrate the scientific necessity and sufficiency of their proposed studies. The NHLBI emphasizes inclusivity by mandating a Plan for Enhancing Diverse Perspectives (PEDP) to enhance the project's scientific merit, with a budget of up to $450,000 in direct costs available over a maximum project period of three years. Interested applicants should note that the application period opens on January 16, 2025, and the final submission deadline is January 7, 2027; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity aimed at supporting Phase I clinical trials for therapeutic and diagnostic interventions related to heart, lung, blood, and sleep (HLBS) disorders. This initiative seeks to accelerate the development of clinical interventions by funding investigator-initiated studies that demonstrate potential advancements in HLBS health, with a focus on ensuring that applicants are prepared to initiate trials promptly after receiving funding. The funding is capped at $1.5 million per year for a project period of up to three years, contingent on satisfactory progress and milestone completion, with applications opening on January 3, 2025, and the first due date set for February 3, 2025. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-025.html.
    Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity for exploratory R21 grant applications focused on secondary analyses of existing human datasets related to heart, lung, blood diseases, and sleep disorders. The objective of this grant is to stimulate innovative research by utilizing existing datasets to explore novel scientific ideas and develop impactful biomedical tools and technologies, without the need for new primary data collection. This initiative is crucial for advancing public health research aligned with NHLBI priorities, with an annual funding commitment of up to $2,187,000 over three years, supporting approximately eighteen new awards each year, with a maximum of $75,000 in direct costs per application for a two-year project period. Interested applicants can find more information and application guidelines at NIH Grants, and should note that the application deadline is January 7, 2026.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders," aimed at supporting investigator-initiated Phase I clinical trials for heart, lung, blood, and sleep (HLBS) disorders in both adults and children. This grant (R61/R33) facilitates funding for essential preclinical activities and the execution of clinical trials, structured in two phases: the R61 phase focuses on preparatory tasks, while the R33 phase involves the actual trial conduct, guided by specific milestones. This initiative is crucial for advancing research that addresses significant health challenges associated with HLBS disorders. Interested applicants can submit proposals starting January 3, 2025, with a maximum project period of five years, and should direct inquiries to grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-026.html.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NHLBI Early Phase Clinical Trials (R33), aimed at supporting investigator-initiated Phase I clinical trials for therapeutic and diagnostic interventions targeting heart, lung, blood, and sleep (HLBS) disorders. Applicants are required to be prepared to initiate their clinical trials within the first quarter of the project period and must demonstrate readiness in obtaining necessary regulatory approvals, including FDA and IRB, prior to the award. This funding is crucial for addressing unmet medical needs through innovative research, with a maximum budget of $1.515 million per year and a project duration of up to three years, contingent upon achieving specific milestones. Interested applicants should note the application deadline of June 4, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further details.
    NINDS Program Project Grant (P01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering the Program Project Grant (P01) to support innovative, collaborative research addressing significant scientific questions within its mission. This grant encourages multi-disciplinary projects that are interdependent, allowing for greater scientific advancements than individual efforts, and applications may include clinical trials, although those focused on intervention effectiveness should seek different funding opportunities. Eligible applicants include higher education institutions, nonprofits, and governmental entities, with funding of up to $1 million in direct costs per year available for a maximum project period of five years. Interested parties should consult with NINDS staff early in the proposal process, with the application submission period opening on April 25, 2024, and due by May 25, 2024; for further inquiries, contact grantsinfo@nih.gov.
    NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is inviting applications for the Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed) grant. This funding opportunity aims to support multi-project research initiatives that focus on infectious, immunologic, and allergic diseases, requiring each application to include at least two synergistic research projects and an administrative core, all centered around a common theme. The initiative is crucial for advancing research in areas such as the biology and pathogenesis of infectious microbes, immune system mechanisms, and the development of vaccines and therapeutics. Interested applicants must submit their proposals electronically via Grants.gov by September 7, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. The funding amount is not limited but should reflect the actual needs of the proposed projects.
    Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), is offering a funding opportunity titled "Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)." This grant aims to support the development and validation of innovative technologies that address significant gaps in heart, lung, blood, and sleep (HLBS) research, focusing on advancing diagnostic and therapeutic solutions with promising preliminary data. Eligible applicants include a wide range of institutions and organizations, with a budget ceiling of $350,000 in direct costs per year, and total funding commitments expected to reach $2,156,000 annually for the next three fiscal years. The application deadline is set for January 11, 2025, and further details can be found on the NIH grants website or by contacting NIH Grants Information at grantsinfo@nih.gov.
    NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for R34 Clinical Trial Pilot Studies aimed at supporting research that informs the planning of Phase II-IV clinical trials focused on heart, lung, blood, and sleep disorders. Applicants are required to demonstrate that their proposed studies are essential for the design of future trials and must include a Plan for Enhancing Diverse Perspectives (PEDP) to promote diversity within research teams. This initiative is critical for advancing clinical practice and understanding in these vital health areas, with awards of up to $450,000 available over three years. Interested applicants should submit their proposals by January 7, 2027, and can find additional information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.